Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.8.3805

CYP3A4 Expression in Breast Cancer and its Association with Risk Factors in Mexican Women  

Floriano-Sanchez, Esau (Section of Research and Graduate Studies, Instituto Politecnico Nacional)
Rodriguez, Noemi Cardenas (Laboratory of Neurochemistry, Instituto Nacional de Pediatria)
Bandala, Cindy (Department of Research Support, Instituto Nacional de Rehabilitacion)
Coballase-Urrutia, Elvia (Laboratory of Neurochemistry, Instituto Nacional de Pediatria)
Lopez-Cruz, Jaime (Service of Pathology, Hospital Militar de Especialidades de la Mujer y Neonatologia)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.8, 2014 , pp. 3805-3809 More about this Journal
Abstract
Background: In Mexico, breast cancer (BCa) is the leading type of cancer in women. Cytochrome P450 (CYP450) is a superfamily of major oxidative enzymes that metabolize carcinogens and many antineoplastic drugs. In addition, these enzymes have influence on tumor development and tumor response to therapy. In this report, we analyzed the protein expression in patients with BCa and in healthy women. Links with some clinic-pathological characteristic were also assessed. Materials and Methods: Immunohistochemical analyses were conducted on 48 sets of human breast tumors and normal breast tissues enrolled in Hospital Militar de Especialidades de la Mujer y Neonatologia and Hospital Central Militar, respectively, during the time period from 2010 to 2011. Informed consent was obtained from all participants. Statistical analysis was performed using ${\chi}^2$ or Fisher exact tests to estimate associations and the Mann Whitney U test for comparison of group means. Results: We found a significant CYP3A4 overexpression in BCa stroma and gland regions in comparison with healthy tissue. A significant association between protein expression with smoking, alcoholism and hormonal contraceptives use was also observed. Additionally, we observed estrogen receptor (ER) and progesterone receptor (PR) positive association in BCa. Conclusions: We suggest that CYP3A4 expression promotes BCa development and can be used in the prediction of tumor response to different treatments. One therapeutic approach may thus be to block CYP3A4 function.
Keywords
Breast cancer; CYP3A4; protein expression; gene environment interactions; Mexico;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Wang-Rodriguez J, Cross K, Gallagher S, et al (2002). Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol, 15, 853-61.   DOI   ScienceOn
2 Lown KS, Bailey DG, Fontana RJ, et al (1997). Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest, 99, 2545-53.   DOI   ScienceOn
3 Mc Fadyen MCE, Melvin WT, Murray GI (2004). Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther, 3, 363-71.
4 Mendez -Estrada RO, Valencia M, Melendez Torres JM (2006). Menarche age in teenagers of the Northwest of Mexico. Arch Latinoam Nutr, 5, 1-3.
5 Michael M, Doherty MM (2007). Drug metabolism by tumours: its nature, relevance and therapeutic implications. Expert Opin Drug, 3, 786-03.
6 Mitra R, Gou Z, Milani M, et al (2011). CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducig nuclear translocation of phospho-Stat3 through biosynthesis of (+)-14, 15-epoxyeicosatrienoin acid (EET). J Biol Chem, 286, 17543-59.   DOI   ScienceOn
7 Garrido-Latorre EC, Lazcano-Ponce L, Lopez-Carrillo M, et al (1996). Age of natural menopause among women in Mexico city. Int J Gynaecol Obstet, 53, 159-66.   DOI   ScienceOn
8 Canchola AJ, Anton-Culver H, Bernstein L, et al (2012). Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer Causes Control, [Epub ahead of print].
9 Cardenas-Rodriguez N, Lara-Padilla E, Bandala C, et al (2012). CYP2W1, CYP4F11 and CYP8A1 polymorphisms and interaction of CYP2W1 genotypes with risk factors in Mexican women with breast cancer. Asian Pac J Cancer Prev, 13, 837-46.   과학기술학회마을   DOI   ScienceOn
10 Chu W, Fyles A (2007). Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis, 28, 2139-42.   DOI   ScienceOn
11 Weiss J, Haefeli WE (2011). Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro. Cancer Chemother Pharmacol, 68, 1093-8.   DOI
12 World Health Organization (2012). www.who.int/mediacentre/factsheets/fs297/es/index.html.
13 Xing MY, Xu SZ, Shen P (2014). Effect of low-fat diet on breast cancer survival:a meta-analysis. Asian Pac J Cancer Prev, 15, 1141-4.   과학기술학회마을   DOI   ScienceOn
14 Zheng W, Jin F, Dunning LA, et al (2001). Epidemiological study of urinary 6beta-hydroxycortisol to cortisol ratios and breast cancer risk. Cancer Epidemiol Biomarkers Prev, 10, 237-42.
15 Zhu BT, Conney AH (1998b). Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res, 58, 2269-77.
16 Miyoshi Y, Taguchi T, Kim SJ, et al (2005). Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. Breast Cancer, 12, 11-5.   DOI
17 Nelson HD, Zakher B, Cantor A, et al (2012). Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med, 15, 635-48.
18 Niwa T, Yabusaki Y, Honma K, et al (1998). Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica, 28, 539-47.   DOI
19 Shapiro C, Recht A (2001). Side effects of adjuvant treatment of breast cancer. N Engl J Med, 344, 1997-2008.   DOI   ScienceOn
20 Shou M, Korzekwa KR, Brooks EN, et al (1997). Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis, 18, 207-14.   DOI   ScienceOn
21 Guengerich FP (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol, 39, 1-17.   DOI   ScienceOn
22 Haas S, Pierl C, Harth V, et al (2006). Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas. Int J Cancer, 119, 1785-91.   DOI   ScienceOn
23 Hassan BA, Yusoff ZB (2011). Genetic polymorphisms in the three Malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 12, 185-91.
24 Huang Z, Fasco MJ, Figge HL, et al (1996). Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos, 24, 899-05.
25 Jacquemier JD, Penault-Llorca FM, Bertucci F, et al (1998). Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. J Pathol, 184, 130-5.   DOI
26 Bruno RD, Njar VC (2007). Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem, 15, 5047-60.   DOI   ScienceOn
27 Bandala C, Floriano-Sanchez E, Cardenas-Rodriguez N, Lopez-Cruz J, Lara-Padilla E (2012). RNA Expression of cytochrome P450 in Mexican women with breast cancer. Asian Pac J Cancer Prev, 13, 2647-53.   과학기술학회마을   DOI   ScienceOn
28 Basseville A, Preisser L, de CarneTrecesson S, et al (2011). Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol Cancer, 10, 80-92.
29 Blacam C, Ogunleye AA, Momoh AO, et al (2012). High body mass index and smoking predict morbidity in breast cancer surgery: a multivariate analysis of 26,988 patients from the national surgical quality improvement program database. Ann Surg, 255, 551-5.   DOI
30 Sistema Nacional de Informacion en Salud (2012). www.sinais.salud.gob.mx/basesdedatos/estandar.html.
31 Takahara T, Nitta H, Hasegawa Y, et al (2011). Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation-interactions between calcineurin inhibitor. Transplant Proc, 4, 2800-5.
32 Torres-Mejia G, Cupul-Uicab LA, Allen B, et al (2005). Comparative study of correlates of early age at menarche among Mexican and Egyptian adolescents. Am J Hum Biol, 17, 54-8.
33 Vaclavikova R, Hubackova M, Stribrna-Sarmanova J, et al (2007). RNA expression of cytochrome P450 in breast cancer patients. Anticancer Res, 27, 4443-50.
34 Lopez-Carrillo L, Bravo-Alvarado J, Poblano-Verastegui O, et al (1997). Reproductive determinants of breast cancer in Mexican women. Ann N Y Acad Sci, 837, 537-50.   DOI   ScienceOn
35 Kim SY, Suzuki N, Santosh Laxmi YR, et al (2003). Alphahydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem Res Toxicol, 16, 1138-44.   DOI   ScienceOn
36 Knaul FM, Lopez Carrillo L, Lazcano Ponce E, et al (2009). Cancer de mama: un reto para la sociedad y los sistemas de salud. Salud Publica Mex, 51, 135-7.   DOI
37 LIatrakis G, Iavazzo C, Zervoudis S, et al (2011). The role of oral contraception use in the occurrence of breast cancer. A retrospective study of 405 patients. Clin Exp Obstet Gynecol, 38, 225-7.
38 Lopez-Carrillo L (2003). El cancer mamario: epidemiologia y prevencion. In: Tamayo RP. El cancer en Mexico. Mexico, D.F.: El Colegio Nacional, 443-56.
39 Ragin CC, Langevin S, Rubin S, et al (2010). Review of studies on metabolic genes and cancer in populations of African descent. Genet Med, 12, 12-8.   DOI   ScienceOn